Home/Pipeline/IRT Platform (e.g., Influenza)

IRT Platform (e.g., Influenza)

Influenza Prevention

Research/Pre-clinicalActive

Key Facts

Indication

Influenza Prevention

Phase

Research/Pre-clinical

Status

Active

Company

Biological Mimetics

About Biological Mimetics

Biological Mimetics is a private, pre-revenue biotechnology company with a 25+ year history, specializing in novel vaccine and diagnostic platforms. Its lead technologies include IRT (Immune Refocusing Technology) for creating more broadly protective vaccines and MDP (Manganese-Decapeptide-Phosphate) for pathogen inactivation, with an advanced program in ultraIPV (inactivated polio vaccine). The company also collaborates on FAST, a portable CRISPR-based diagnostic tool designed for low-resource settings. BMI operates through partnerships to advance its platforms toward the market.

View full company profile

Therapeutic Areas

Infectious Disease

Other Influenza Prevention Drugs

Drug	Company	Phase	Status
mRNA-based Broad Flu Vaccine	Micron Biomedical	Pre-clinical	Active
CaPtivaX Nasal Influenza Vaccine	CaPtivate Pharmaceuticals	Pre-clinical	Active
Next-Generation Influenza Vaccines	Fluart Innovative Vaccines	Not Disclosed	Active
HD-MAP Influenza Vaccine	Vaxxas	Phase 2/3	Active